CAMV-01

CAMV-01 is a peptide-based immunotherapy candidate developed by Cambium Oncology that targets the vasoactive intestinal peptide (VIP) and its receptors, VPAC1 and VPAC2 (collectively known as the VIP/VPAC axis). VIP is a neuropeptide that often acts as a neuroimmune checkpoint in the tumor microenvironment, where high levels of VIP can suppress T-cell activity and promote tumor growth. As a peptide antagonist, CAMV-01 is designed to block VIP-receptor signaling, thereby reversing immune suppression and enhancing T cell-mediated anti-tumor responses. The drug is primarily being developed for the treatment of solid tumors, such as colon and pancreatic cancers, which frequently overexpress VIP and are often less responsive to standard PD-1/PD-L1 checkpoint inhibitors.